- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04445987
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
A Phase 2, Multicenter, Open-Label Study of the Long-Term Safety of ARQ-154 Foam 0.3% in Subjects With Seborrheic Dermatitis
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90212
- Arcutis Biotherapeutics Clinical Site 59
-
Encino, California, United States, 91436
- Arcutis Biotherapeutics Clinical Site 51
-
Fountain Valley, California, United States, 92708
- Arcutis Biotherapeutics Clinical Site 75
-
Fremont, California, United States, 94538
- Arcutis Biotherapeutics Clinical Site 19
-
Los Angeles, California, United States, 90036
- Arcutis Biotherapeutics Clinical Site 62
-
San Diego, California, United States, 92123
- Arcutis Biotherapeutics Clinical Site 64
-
Santa Monica, California, United States, 90404
- Arcutis Biotherapeutics Clinical Site 21
-
-
Florida
-
Aventura, Florida, United States, 33180
- Arcutis Biotherapeutics Clinical Site 53
-
Coral Gables, Florida, United States, 33134
- Arcutis Biotherapeutics Clinical Site 42
-
Delray Beach, Florida, United States, 33484
- Arcutis Biotherapeutics Clinical Site 57
-
Miami, Florida, United States, 33144
- Arcutis Biotherapeutics Clinical Site 24
-
Sanford, Florida, United States, 32771
- Arcutis Biotherapeutics Clinical Site 65
-
Tampa, Florida, United States, 33613
- Arcutis Biotherapeutics Clinical Site 12
-
-
Illinois
-
Rolling Meadows, Illinois, United States, 60008
- Arcutis Biotherapeutics Clinical Site 10
-
-
Indiana
-
Plainfield, Indiana, United States, 46168
- Arcutis Biotherapeutics Clinical Site 22
-
-
Kentucky
-
Louisville, Kentucky, United States, 40217
- Arcutis Biotherapeutics Clinical Site 15
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- Arcutis Biotherapeutics Clinical Site 52
-
-
Maryland
-
Rockville, Maryland, United States, 20850
- Arcutis Biotherapeutics Clinical Site 28
-
-
Massachusetts
-
Brighton, Massachusetts, United States, 02135
- Arcutis Biotherapeutics Clinical Site 73
-
-
Michigan
-
Clinton Township, Michigan, United States, 48038
- Arcutis Biotherapeutics Clinical Site 40
-
Detroit, Michigan, United States, 48202
- Arcutis Biotherapeutics Clinical Site 20
-
Fort Gratiot, Michigan, United States, 48059
- Arcutis Biotherapeutics Clinical Site 58
-
-
Minnesota
-
Fridley, Minnesota, United States, 55432
- Arcutis Biotherapeutics Clinical Site 14
-
-
Nevada
-
Las Vegas, Nevada, United States, 89148
- Arcutis Biotherapeutics Clinical Site 50
-
-
New Hampshire
-
Portsmouth, New Hampshire, United States, 03801
- Arcutis Biotherapeutics Clinical Site 56
-
-
New York
-
Bronx, New York, United States, 10462
- Arcutis Biotherapeutics Clinical Site 63
-
New York, New York, United States, 10029
- Arcutis Biotherapeutics Clinical Site 55
-
-
North Carolina
-
High Point, North Carolina, United States, 27262
- Arcutis Biotherapeutics Clinical Site 23
-
-
Ohio
-
Bexley, Ohio, United States, 43209
- Arcutis Biotherapeutics Clinical Site 18
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Arcutis Biotherapeutics Clinical Site 29
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Arcutis Biotherapeutics Clinical Site 27
-
-
South Carolina
-
Charleston, South Carolina, United States, 29407
- Arcutis Biotherapeutics Clinical Site 76
-
-
Texas
-
Arlington, Texas, United States, 76011
- Arcutis Biotherapeutics Clinical Site 13
-
Austin, Texas, United States, 78759
- Arcutis Biotherapeutics Clinical Site 11
-
College Station, Texas, United States, 77845
- Arcutis Biotherapeutics Clinical Site 41
-
Houston, Texas, United States, 77056
- Arcutis Biotherapeutics Clinical Site 25
-
Pflugerville, Texas, United States, 78660
- Arcutis Biotherapeutics Clinical Site 26
-
San Antonio, Texas, United States, 78213
- Arcutis Biotherapeutics Clinical Site 54
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Arcutis Biotherapeutics Clinical Site 17
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants legally competent to sign and give informed consent or (for adolescents) assent.
- Males and females ages 9 years and older (inclusive) at the time of consent.
- Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at all study visits.
Post-menopausal women with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization.
Cohort 1 only:
Subjects with seborrheic dermatitis who met eligibility criteria for a prior ARQ-154 study, successfully completed a prior ARQ-154 study through final visit and are able to immediately enroll into this long-term safety study on the final visit of the previous ARQ-154 study.
Cohort 2 subjects that have not participated in a prior ARQ-154 study:
- Clinical diagnosis of seborrheic dermatitis of at least 3 months duration as determined by the Investigator. Stable disease for the past 4 weeks.
- Seborrheic dermatitis of the scalp and/or face and/or trunk and/or intertriginous areas up to ≤20% BSA involvement.
- An Investigator Global Assessment (IGA) of disease severity of at least Moderate ('3') at Day 1.
Overall Assessment of Erythema and Overall Assessment of Scaling scores of Moderate ('2') at Day 1.
Cohort 2 subjects that have participated in a prior ARQ-154 study:
- Clinical diagnosis of seborrheic dermatitis of at least 3 months duration as determined by the Investigator.
- Seborrheic dermatitis of the scalp and/or face and/or trunk and/or intertriginous areas up to ≤20% BSA involvement.
Exclusion Criteria:
- Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.
- Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.
- Subjects unable to apply investigational product to the scalp due to physical limitation.
- Known allergies to excipients in ARQ-154 foam.
- Subjects who cannot discontinue the use of strong P-450 cytochrome inhibitors e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, suboxone and telithromycin during the study period.
Known or suspected:
- severe renal insufficiency or moderate to severe hepatic disorders
- history of severe depression, suicidal ideation or C-SSRS indicative of suicidal ideation, whether lifetime or recent/recurrent.
- Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
- Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
- Subjects with a history of chronic alcohol or drugs abuse within 6 months of initiation of investigational product.
- Current or a history of cancer within 5 years with the exception of fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.
- Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members that live in the same household of enrolled subjects.
Cohort 1 only:
- Subjects who experienced an ARQ-154 treatment-related AE or a serious AE (SAE) that precluded further treatment with ARQ-154 foam in a prior ARQ-154 study.
Subjects that use any Excluded Medication and Treatments.
Cohort 2 only:
- Subjects who cannot discontinue treatment with therapies for the treatment of seborrheic dermatitis prior to the Day 1 visit and during the study according to Excluded Medications and Treatments.
Subjects with PHQ-8 >10 or modified PHQ-A >10 at Screening or Day 1.
Cohort 2 subjects that have participated in a prior ARQ-154 study:
- Subjects who experienced an ARQ-154 treatment-related AE or a serious AE (SAE) that precluded further treatment with ARQ-154 foam in a prior ARQ-154 study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Long-term safety of ARQ-154
Open-label, Long-term Safety of ARQ-154
|
ARQ-154 foam 0.3% applied once daily for 52 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Emergent Adverse Events
Time Frame: 52 Weeks
|
Occurrence of treatment emergent adverse events
|
52 Weeks
|
Serious Adverse Events
Time Frame: 52 Weeks
|
Occurrence of treatment serious adverse events
|
52 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Investigator Global Assessment
Time Frame: 52 Weeks
|
Achievement of an IGA score of 'completely clear' or 'almost clear' as observed over time.
This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4).
|
52 Weeks
|
Investigator Global Assessment
Time Frame: 52 Weeks
|
A 2-grade improvement in IGA from Baseline as observed over time.
This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4).
|
52 Weeks
|
Investigator Global Assessment
Time Frame: 52 Weeks
|
Achievement of an IGA score of 'completely clear' or 'almost clear' plus a 2-grade improvement in IGA from baseline as observed at Week 12, Week 24.
This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4).
|
52 Weeks
|
Duration of Response
Time Frame: 52 Weeks
|
Duration of IGA Success, defined as the time from the first observation of IGA Success to the last time a subject's disease response meets the criteria for IGA Success.
The duration of IGA Success for subjects who end treatment in IGA Success will be censored at the last disease assessment date.
|
52 Weeks
|
Treatment Free Interval
Time Frame: 52 Weeks
|
Treatment-free interval, defined among subjects who achieve a 'completely clear' IGA and stop treatment to all lesions, as the time from attainment of a score of 'clear' to re-starting study drug.
|
52 Weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: David Berk, MD, Arcutis Biotherapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARQ-154-214
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seborrheic Dermatitis
-
Galderma R&DCompletedScalp Seborrheic DermatitisBelgium, France, Germany, Korea, Republic of, Mexico
-
Promius Pharma, LLCCompleted
-
University Hospital, RouenCompletedSevere Seborrheic DermatitisFrance
-
LEO PharmaBayerCompletedSeborrheic Dermatitis on the FaceGermany
-
Astion Pharma A/SCompletedSeborrheic Dermatitis
-
Dermatology Specialists ResearchNovartisCompletedSeborrheic DermatitisUnited States
-
University of Alabama at BirminghamCompletedSeborrheic DermatitisUnited States
-
Medicis Global Service CorporationCompletedSeborrheic DermatitisUnited States
-
Lexington International, LLCCompleted
-
L'OrealCompleted
Clinical Trials on ARQ-154
-
Arcutis Biotherapeutics, Inc.CompletedScalp PsoriasisUnited States, Canada
-
Arcutis Biotherapeutics, Inc.CompletedSeborrheic DermatitisUnited States, Canada
-
Arcutis Biotherapeutics, Inc.CompletedSeborrheic DermatitisUnited States, Canada
-
Arcutis Biotherapeutics, Inc.CompletedPlaque PsoriasisUnited States, Australia, Bulgaria, Canada
-
AbbVieCompleted
-
Shanghai Zhimeng Biopharma, Inc.RecruitingHealthy VolunteersUnited States
-
Shanghai Zhimeng Biopharma, Inc.CompletedHealthy VolunteersAustralia
-
Arcutis Biotherapeutics, Inc.CompletedPsoriasisCanada, United States
-
Arcutis Biotherapeutics, Inc.CompletedChronic Hand EczemaUnited States, Australia, Canada
-
AbbVieTerminatedCrohn's DiseaseUnited States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Slovakia, Spain, Taiwan, United...